Advertisement
Screener

INTERPACE BIOSCIENCES, INC. (IDXGD) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

INTERPACE BIOSCIENCES, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

INTERPACE BIOSCIENCES, INC. (IDXGD) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $266.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-10

  • INTERPACE BIOSCIENCES, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $266.00K.
  • INTERPACE BIOSCIENCES, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $831.00K, a 52.62% decline year-over-year.
  • INTERPACE BIOSCIENCES, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $22.75M, a 1119.95% increase year-over-year.
  • INTERPACE BIOSCIENCES, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $1.01M, a 42.49% decline year-over-year.
  • INTERPACE BIOSCIENCES, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was $24.98M, a 259.69% increase from fiscal 2024.
  • INTERPACE BIOSCIENCES, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $6.95M, a 206.80% increase from fiscal 2023.
  • INTERPACE BIOSCIENCES, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was $2.26M.
  • INTERPACE BIOSCIENCES, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$5.87M.
Period endIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed
2026-06-30$266.00K
10-Q · filed 2026-08-10
$1.10M
10-Q · filed 2026-08-10
$23.85M
derived: sum of 3 quarters · filed 2026-08-10
$24.86M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$831.00K
10-Q · filed 2026-05-12
$23.58M
derived: sum of 2 quarters · filed 2026-05-12
$24.59M
derived: sum of 3 quarters · filed 2026-05-12
$24.06M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$22.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$23.76M
derived: sum of 2 quarters · filed 2026-03-30
$23.23M
derived: sum of 3 quarters · filed 2026-08-10
$24.98M
10-K · filed 2026-03-30
2025-09-30$1.01M
10-Q · filed 2025-11-12
$478.00K
derived: sum of 2 quarters · filed 2026-08-10
$2.23M
10-Q · filed 2025-11-12
$4.10M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30-$533.00K
10-Q · filed 2026-08-10
$1.22M
10-Q · filed 2026-08-10
$3.09M
derived: sum of 3 quarters · filed 2026-08-10
$4.84M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$1.75M
10-Q · filed 2026-05-12
$3.62M
derived: sum of 2 quarters · filed 2026-05-12
$5.38M
derived: sum of 3 quarters · filed 2026-05-12
$7.89M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$1.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$3.62M
derived: sum of 2 quarters · filed 2026-03-30
$6.13M
derived: sum of 3 quarters · filed 2026-03-30
$6.95M
10-K · filed 2026-03-30
2024-09-30$1.76M
10-Q · filed 2025-11-12
$1.36M
10-Q · filed 2024-11-08
$4.27M
derived: sum of 2 quarters · filed 2025-11-12
$5.08M
10-Q · filed 2025-11-12
$4.07M
10-Q · filed 2024-11-08
$6.07M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$2.51M
10-Q · filed 2025-08-07
$2.14M
10-Q · filed 2024-08-08
$3.32M
10-Q · filed 2025-08-07
$2.71M
10-Q · filed 2024-08-08
$4.32M
derived: sum of 3 quarters · filed 2025-08-07
$4.21M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$812.00K
10-Q · filed 2025-05-08
$572.00K
10-Q · filed 2024-05-09
$1.80M
derived: sum of 2 quarters · filed 2025-05-08
$1.70M
derived: sum of 3 quarters · filed 2025-05-08
$2.48M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$992.00K
derived: 10-K 12 month − 10-K 9 month · filed 2025-03-31
$892.00K
derived: sum of 2 quarters · filed 2025-03-31
$1.67M
derived: sum of 3 quarters · filed 2025-03-31
$2.26M
10-K · filed 2025-03-31
$1.11M
10-K · filed 2024-04-01
2023-09-30-$100.00K
10-K · filed 2025-03-31
-$528.00K
10-Q · filed 2023-11-08
$679.00K
derived: sum of 2 quarters · filed 2025-03-31
$1.27M
10-K · filed 2025-03-31
$297.00K
10-Q · filed 2023-11-08
-$135.00K
derived: sum of 4 quarters · filed 2025-03-31
2023-06-30$779.00K
10-K · filed 2025-03-31
$395.00K
10-Q · filed 2023-08-09
$1.37M
10-K · filed 2025-03-31
$825.00K
10-Q · filed 2023-08-09
-$35.00K
derived: sum of 3 quarters · filed 2025-03-31
-$1.29M
derived: sum of 4 quarters · filed 2025-03-31
2023-03-31$593.00K
10-K · filed 2025-03-31
$430.00K
10-Q · filed 2023-05-12
-$814.00K
derived: sum of 2 quarters · filed 2025-03-31
-$2.07M
derived: sum of 3 quarters · filed 2025-03-31
-$4.13M
derived: sum of 4 quarters · filed 2025-03-31
2022-12-31-$1.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
-$2.66M
derived: sum of 2 quarters · filed 2024-04-01
-$4.73M
derived: sum of 3 quarters · filed 2024-04-01
-$5.87M
10-K · filed 2024-04-01
2022-09-30-$1.25M
10-Q · filed 2023-11-08
-$3.32M
derived: sum of 2 quarters · filed 2023-11-08
-$4.46M
10-Q · filed 2023-11-08
-$6.20M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30-$2.07M
10-Q · filed 2023-08-09
-$3.89M
10-Q · filed 2022-08-15
-$3.20M
10-Q · filed 2023-08-09
-$6.08M
10-Q · filed 2022-08-15
-$4.94M
derived: sum of 3 quarters · filed 2023-08-09
-$6.26M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$1.14M
10-Q · filed 2023-05-12
-$2.19M
10-Q · filed 2022-05-16
-$2.88M
derived: sum of 2 quarters · filed 2023-05-12
-$4.20M
derived: sum of 3 quarters · filed 2023-05-12
-$7.58M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$1.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27
-$3.06M
derived: sum of 2 quarters · filed 2023-03-27
-$6.45M
derived: sum of 3 quarters · filed 2023-03-27
-$7.04M
10-K · filed 2023-03-27
2021-09-30-$1.32M
10-Q · filed 2022-11-14
-$4.71M
derived: sum of 2 quarters · filed 2022-11-14
-$5.29M
10-Q · filed 2022-11-14
2021-06-30-$3.39M
10-Q · filed 2022-08-15
-$7.54M
10-Q · filed 2022-08-15
2021-03-31-$4.15M
10-Q · filed 2022-05-16